SCYNEXIS, Inc. (SCYX) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2024
Loading P/E history...
SCYX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, SCYNEXIS, Inc. (SCYX) trades at a price-to-earnings ratio of -5.6x, with a stock price of $0.96 and trailing twelve-month earnings per share of $-0.20.
The current P/E is 284% below its 5-year average of 3.1x. Over the past five years, SCYX's P/E has ranged from a low of 0.7x to a high of 7.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SCYX trades at a 125% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SCYX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SCYX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SCYX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $166B | 19.8 | 0.15Best | +1684%Best | |
| $277B | 15.4Lowest | 0.73 | +8% | |
| $151B | 19.5 | - | -4% | |
| $30B | 22.8 | 0.56 | +5% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SCYX Historical P/E Data (2023–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $1.47 | $2.00 | 0.7x | -76% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $2.23 | $1.28 | 1.7x | -43% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $2.28 | $1.12 | 2.0x | -34% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $2.95 | $0.38 | 7.8x | +153% |
Average P/E for displayed period: 3.1x
See SCYX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCYX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SCYX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSCYX — Frequently Asked Questions
Quick answers to the most common questions about buying SCYX stock.
Is SCYX stock overvalued or undervalued?
SCYX trades at -5.6x P/E, below its 5-year average of 3.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SCYX's valuation compare to peers?
SCYNEXIS, Inc. P/E of -5.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SCYX's PEG ratio?
SCYX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2024.